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Introduction 
Cardiovascular (CV) aging involves all the changes that occur in the structure and functions of this system 
over the years resulting in well-defined phenotypic changes which render this system prone to disease.  
The prevalence of age-related pathologies, such as cardiovascular disease (CVD), is increasing with the 
rising average age population constituting one of the fists causes of mortality. In consequence, better 
knowledge of the effect of aging on the CV system is needed for developing new and effective treatments 
in order to prevent or delay these alterations. Investigations targeting the arteries are bringing interesting 
results that may end in new treatments to prevent CV aging and, consequently, CVD. 
 
 
 
 
 
Materials and Methods 
• Search on PubMed database: scientific literature 
including published reviews and papers.  
• Criteria of selection: key words, quality and 
publication date. 
• Key words: “cardiovascular”, “aging”, “senescence”, 
“arterial stiffness”, “pharmacological treatment”, 
“drugs” and  “statins”. 
The most plausible mechanisms are: improvement in endothelial function and consequent vasodilation 
and favourable structural alterations in arterial wall. 
 
• Search of treatments targeting CV aging is of great importance for public health. 
• Even though mechanisms of CV aging are almost fully understood, an even better 
understanding of the arterial aging process is needed. 
• Reduction in arterial stiffness → decrease in arterial age → reduction in CV 
mortality and morbidity.  
• There are still controversies about the use of statins or arterial aging and the 
mechanisms involved in their action.  
Conclusions 
 
Additional animal and human studies, especially long 
term prospective and larger studies, are required to 
confirm if statins administered preventively are able to: 
• Reduce CV aging through improving arterial stiffness 
• Reduce the incidence of CV events 
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Fig. 3 Diagram representing the steps in cholesterol synthesis 
and the mechanisms of action of statins. Adapted from: [3]. 
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•  Loss of myocytes and hypertrophy of the remaining ones 
• Reduction in the number of peacemaker cells 
• Diastolic dysfunction 
•  maximal heart rate, maximal cardiac output and maximal VO2 
•  Endothelial dysfunction 
•  Arteriosclerosis 
• Arterial stiffness 
• ↑ systolic arterial pressure 
 
‒ Changes in intimal and medial layers in large-sized and medium-sized arteries.  
‒ 1st  sign of CV system degeneration. 
‒ Arterial stiffness:  
o Collagen deposition and elastin fragmentation in the subendothelial space 
due to repeated mechanical stress.  
o Measured with pulse wave velocity (PWV): 
↑PWV  ↑ arterial stiffness  ↑ risk of CV events 
Therapies targeting 
arterial aging focus on 
  arterial stiffness 
progression  
 increase of 
arterial pulse 
 whole body age 
 CV risk 
•Main use: plasma cholesterol reduction → HMG CoA-reductase inhibitors 
•Other beneficial pleiotropic effects 
Statins 
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Figure 2. General 
perspective of the 
chain of events 
linking aging to CVD. 
Figure adapted from 
[2]. 
1. Endothelium changes: important role in arterial aging. Endothelial cell turnover and oxidative stress induce telomere 
shortening and, consequently, cell senescence.  
2. Oxidative stress: the free radical theory of aging states that organisms age because of the production of intracellular 
reactive oxygen species (ROS) over time because there is an imbalance between the oxidative and anti-oxidative 
system. The two main causes of decreased expression of eNOS (endothelial nitric  oxide synthase) are:  
• ↑ degradation of L-arginine, a major eNOS substrate, by arginase II. 
• ↑ degradation of tetrahydrobiopterin (BH 4), an important cofactor for eNOS activity, by oxidative stress.  
3. "Inflammaging“: upregulation of the inflammatory response with progressing old age → vasculature is more 
susceptible to atherogenesis. It also  stimulates the rupture of atherosclerotic plaques. 
 
Strategies Targeting Arterial Aging 
Arterial system is considered as a suitable target for anti-aging strategies because it 
connects all the organs in the body. Middle-aged individuals already present age-
related reversible arterial wall changes that progress with aging, underlying the 
development of CVD.  
Evidence of the Use Of Statins in Arterial Aging 
• Antioxidant properties:  
     ‒  circulating LDL cholesterol and markers of                     
oxidation 
    ‒ ↑ NO availability  
•  oxidative stress + inflammation  destiffening 
properties  
● ↑ circulating endothelial progenitors 
•  Stability of atherosclerotic plaques:  
  ‒  accumulation of esterified cholesterol into 
macrophages 
     ‒  platelet clumping and aggregation 
• Benefits for statin administration in reduction of 
arterial stiffness above CV risk reduction have not 
been demonstrated. 
 
• Treatment discontinuation reduces the 
potential benefits and increases risk of adverse 
medication events.  
 
• Adverse reactions in the muscular system, liver 
and kidneys. Different frequency of appearance, 
but often reported to be of low risk.  
 
• Lack of information about efficiency, safety and 
tolerability when used for CV aging. 
Arterial Aging 
Figure 1. Images extracted from: [1]. 
• To compile the current knowledge 
about the process of CV aging: 
changes that occur and the 
mechanisms involved. 
• To analyse the scientific evidences 
of the use of statins  for prevention 
of arterial aging. 
